Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $30.8333.

STOK has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective for the company. BTIG Research raised their target price on Stoke Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research note on Monday. Wedbush raised their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Stoke Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $34.94 on Wednesday. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 41.11 and a beta of 1.24. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $35.08. The business has a fifty day moving average price of $21.76 and a 200-day moving average price of $14.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. On average, equities research analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Jonathan Allan sold 14,922 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $20.14, for a total value of $300,529.08. Following the completion of the transaction, the general counsel owned 18,176 shares in the company, valued at $366,064.64. This trade represents a 45.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Barry Ticho sold 5,501 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the transaction, the insider owned 18,469 shares of the company’s stock, valued at $366,979.03. This trade represents a 22.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold 185,180 shares of company stock worth $4,129,406 in the last 90 days. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after buying an additional 53,004 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock valued at $26,111,000 after buying an additional 168,771 shares during the last quarter. Siren L.L.C. raised its stake in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after buying an additional 247,347 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after buying an additional 293,072 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company’s stock valued at $11,044,000 after buying an additional 70,935 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.